Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2020 - 12 - 07 tags : Phase 3 save search
Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
Published: 2020-12-07 (Crawled : 22:00) - globenewswire.com
AGIO | $29.52 0.31% 0.3% 750K
|
Health Technology
|
| O: -9.8%
H: 0.0%
C: -6.89%
disease phase 3 phase 1 phase 2
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
KROS | $58.345 -1.03% -1.04% 350K
|
Health Technology
|
| O: -0.36%
H: 2.91%
C: -2.8%
results trial phase 3 phase 1 phase 2 preclinical pre-clinical
Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis
Published: 2020-12-07 (Crawled : 13:05) - globenewswire.com
DARE | $0.2838 -3.83% -3.98% 550K
|
Health Technology
|
| O: -6.0%
H: 2.84%
C: -5.67%
positive results phase 3 trial topline
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Published: 2020-12-07 (Crawled : 13:02) - globenewswire.com
ONCT | $8.97 4.3% 4.12% 4.5K
|
Health Technology
|
| O: 48.5%
H: 23.29%
C: 0.76%
phase 3 phase 1 phase 2
Brickell Biotech Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BBI | $2.12 16.04%
|
Health Technology
|
| O: 1.53%
H: 0.03%
C: -1.35%
biotech phase 3
Mustang Bio Announces Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 0.0%
H: 2.47%
C: -19.01%
phase 3 phase 1 phase 2 t-cell
Bellicum Reports Clinical Hold Placed on BPX-601 Phase 1/2 Clinical Trial
Published: 2020-12-07 (Crawled : 13:00) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -2.91%
H: 0.0%
C: -7.0%
trial phase 3 phase 1 phase 2 clinical hold
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Published: 2020-12-07 (Crawled : 12:02) - globenewswire.com
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 61.9%
H: 0.0%
C: -31.37%
positive results phase 3 fibromyalgia
HOOKIPA Interim Phase 1 Monotherapy Data of HB-201 for the Treatment of Advanced HPV16+ Cancers Shows Promising Anti-Tumor Activity and Favorable Tolerability
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
HOOK | $0.7317 -4.34% -4.54% 420K
|
Health Technology
|
| O: 2.13%
H: 8.6%
C: 6.34%
cancer therapy treatment phase 3 phase 1 phase 2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.